Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways

Gene Therapy

Volumn 21, Issue 7, 2014, Pages 682-693

  Gombash, S E ^a,b   Manfredsson, F P ^b   Mandel, R J ^c   Collier, T J ^b   Fischer, D L ^b   Kemp, C J ^b   Kuhn, N M ^b   Wohlgenant, S L ^b   Fleming, S M ^a   Sortwell, C E ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NEUROPROTECTIVE AGENT; OXIDOPAMINE; PLEIOTROPHIN; TYROSINE 3 MONOOXYGENASE; CARRIER PROTEIN; CYTOKINE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; CELL DENSITY; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; FOREFOOT; GENE OVEREXPRESSION; GENE TRANSFER; IMMUNOREACTIVITY; INTRASTRIATAL DRUG ADMINISTRATION; LIMB DEFECT; MALE; NEURITE; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTYPE; STEREOLOGY; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; ADMINISTRATION AND DOSAGE; ANIMAL; CELL LINE; CHEMICALLY INDUCED; COMPARATIVE STUDY; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; METABOLISM; NEURODEGENERATIVE DISEASES; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA;

RATTUS;

ANIMALS; CARRIER PROTEINS; CELL LINE; CORPUS STRIATUM; CYTOKINES; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; MALE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TRANSDUCTION, GENETIC;

EID: 84903890493     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.42     Document Type: Article

References (56)

1. Marks Jr WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: A double-blind, randomised, controlled trial. Lancet Neurol 2010; 9: 1164-1172
2. Marks Jr WJ, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-Associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Lancet Neurol 2008; 7: 400-408
3. Ceregene. Ceregene reports data from Parkinson's disease Phase 2b Study [press release]. Retrived from http://www.ceregene.com/press-041913.asp, 2013
4. NINDS. AAV2-GDNF for Advanced Parkinson's Disease. 2013
5. Gasmi M, Brandon EP, Herzog CD, Wilson A, Bishop KM, Hofer EK, et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-Term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis 2007; 27: 67-76
6. Gasmi M, Herzog CD, Brandon EP, Cunningham JJ, Ramirez GA, Ketchum ET, et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther 2007; 15: 62-68
7. Herzog CD, Dass B, Holden JE, Stansell 3rd J, Gasmi M, Tuszynski MH, et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 2007; 22: 1124-1132
8. Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, et al. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-Associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 2005; 25: 769-777
9. Kirik D, Rosenblad C, Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci 2000; 12: 3871-3882
10. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-Term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000; 20: 4686-4700
11. Rosenblad C, Kirik D, Bjorklund A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp Neurol 2000; 161: 503-516
12. Bartus RT. Translating the therapeutic potential of neurotrophic factors to clinical 'proof of concept': A personal saga achieving a career-long quest. Neurobiol Dis 2012; 48: 153-178
13. Herzog CD, Brown L, Kruegel BR, Wilson A, Tansey MG, Gage FH, et al. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neurobiol Dis 2013; 58: 38-48
14. Hida H, Jung CG, Wu CZ, Kim HJ, Kodama Y, Masuda T, et al. Pleiotrophin exhibits a trophic effect on survival of dopaminergic neurons in vitro. Eur J Neurosci 2003; 17: 2127-2134
15. Marchionini D, Lehrmann E, Chu Y, He B, Sortwell C, Becker K, et al. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res 2007; 1147: 77-88
16. Gombash SE, Lipton JW, Collier TJ, Madhavan L, Steece-Collier K, Cole-Strauss A, et al. Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model. Mol Ther 2012; 20: 544-554
17. Spieles-Engemann AL, Behbehani MM, Collier TJ, Wohlgenant SL, Steece-Collier K, Paumier K, et al. Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss. Neurobiol Dis 2010; 39: 105-115
18. Taravini IR, Chertoff M, Cafferata EG, Courty J, Murer MG, Pitossi FJ, et al. Pleiotrophin over-expression provides trophic support to dopaminergic neurons in parkinsonian rats. Mol Neurodegener 2011; 6: 40
19. Ferrario JE, Rojas-Mayorquin AE, Saldana-Ortega M, Salum C, Gomes MZ, Hunot S, et al. Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats. J Neurochem 2008; 107: 443-452
20. Mi R, Chen W, Hoke A. Pleiotrophin is a neurotrophic factor for spinal motor neurons. Proc Natl Acad Sci USA 2007; 104: 4664-4669
21. Hsueh YP, Sheng M. Regulated expression and subcellular localization of syndecan heparan sulfate proteoglycans and the syndecan-binding protein CASK/LIN-2 during rat brain development. J Neurosci 1999; 19: 7415-7425
22. Rohrbough J, Broadie K. Anterograde Jelly belly ligand to Alk receptor signaling at developing synapses is regulated by Mind the gap. Development 2010; 137: 3523-3533
23. Hayashi N, Oohira A, Miyata S. Synaptic localization of receptor-Type protein tyrosine phosphatase zeta/beta in the cerebral and hippocampal neurons of adult rats. Brain Res 2005; 1050: 163-169
24. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001; 276: 16772-16779
25. Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 2002; 277: 14153-14158
26. Bowden ET, Stoica GE, Wellstein A. Anti-Apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol Chem 2002; 277: 35862-35868
27. Kinnunen T, Raulo E, Nolo R, Maccarana M, Lindahl U, Rauvala H. Neurite outgrowth in brain neurons induced by heparin-binding growth-Associated molecule (HB-GAM) depends on the specific interaction of HB-GAM with heparan sulfate at the cell surface. J Biol Chem 1996; 271: 2243-2248
28. Rauvala H, Huttunen HJ, Fages C, Kaksonen M, Kinnunen T, Imai S, et al. Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility. Matrix Biol 2000; 19: 377-387
29. Maeda N, He J, Yajima Y, Mikami T, Sugahara K, Yabe T. Heterogeneity of the chondroitin sulfate portion of phosphacan/6B4 proteoglycan regulates its binding affinity for pleiotrophin/heparin binding growth-Associated molecule. J Biol Chem 2003; 278: 35805-35811
30. Maeda N, Nishiwaki T, Shintani T, Hamanaka H, Noda M. 6B4 proteoglycan/ phosphacan, an extracellular variant of receptor-like protein-Tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-Associated molecule (HB-GAM). J Biol Chem 1996; 271: 21446-21452
31. Tsui CC, Pierchala BA. The differential axonal degradation of Ret accounts for cell-Type-specific function of glial cell line-derived neurotrophic factor as a retrograde survival factor. J Neurosci 2010; 30: 5149-5158
32. Leitner ML, Molliver DC, Osborne PA, Vejsada R, Golden JP, Lampe PA, et al. Analysis of the retrograde transport of glial cell line-derived neurotrophic factor (GDNF), neurturin, and persephin suggests that in vivo signaling for the GDNF family is GFRalpha coreceptor-specific. J Neurosci 1999; 19: 9322-9331
33. Tomac A, Widenfalk J, Lin LF, Kohno T, Ebendal T, Hoffer BJ, et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc Natl Acad Sci USA 1995; 92: 8274-8278
34. Bartus RT, Brown L, Wilson A, Kruegel B, Siffert J, Johnson Jr EM, et al. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease. Neurobiol Dis 2011; 44: 38-52
35. Gasmi M, Brandon EP, Herzog CD, Wilson A, Bishop KM, Hofer EK, et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-Term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis 2007; 27: 67-76
36. Sun M, Kong L, Wang X, Lu XG, Gao Q, Geller AI. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res 2005; 1052: 119-129
37. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995; 373: 335-339
38. Mandel RJ, Spratt SK, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-Associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 1997; 94: 14083-14088
39. Oiwa Y, Yoshimura R, Nakai K, Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res 2002; 947: 271-283
40. Wang L, Muramatsu S, Lu Y, Ikeguchi K, Fujimoto K, Okada T, et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Therapy 2002; 9: 381-389
41. Kozlowski DA, Connor B, Tillerson JL, Schallert T, Bohn MC. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp Neurol 2000; 166: 1-15
42. McGrath J, Lintz E, Hoffer BJ, Gerhardt GA, Quintero EM, Granholm AC. Adenoassociated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion. Cell Transplant 2002; 11: 215-227
43. Rosenblad C, Martinez-Serrano A, Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 1998; 82: 129-137
44. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci USA 2008; 105: 763-768
45. Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One 2010; 5: E8784
46. Gombash SE, Manfredsson FP, Kemp CJ, Kuhn NC, Fleming SM, Egan AE, et al. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. PLoS One 2013; 8: E81426
47. Burger C, Nguyen FN, Deng J, Mandel RJ. Systemic mannitol-induced hyperosmolality amplifies rAAV2-mediated striatal transduction to a greater extent than local co-infusion. Mol Ther 2005; 11: 327-331
48. Schallert T. Behavioral tests for preclinical intervention assessment. NeuroRx 2006; 3: 497-504
49. Olsson M, Nikkhah G, Bentlage C, Bjorklund A. Forelimb akinesia in the rat Parkinson model: Differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995; 15(Pt 2): 3863-3875
50. Fleming SM, Schallert T, Ciucci MR. Cranial and related sensorimotor impairments in rodent models of Parkinson's disease. Behav Brain Res 2012; 231: 317-322
51. Woodlee MT, Kane JR, Chang J, Cormack LK, Schallert T. Enhanced function in the good forelimb of hemi-parkinson rats: Compensatory adaptation for contralateral postural instability?. Exp Neurol 2008; 211: 511-517
52. Schallert T, Upchurch M, Wilcox RE, Vaughn DM. Posture-independent sensorimotor analysis of inter-hemispheric receptor asymmetries in neostriatum. Pharmacol Biochem Behav 1983; 18: 753-759
53. Schallert T, Upchurch M, Lobaugh N, Farrar SB, Spirduso WW, Gilliam P, et al. Tactile extinction: Distinguishing between sensorimotor and motor asymmetries in rats with unilateral nigrostriatal damage. Pharmacol Biochem Behav 1982; 16: 455-462
54. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000; 39: 777-787
55. Robinson TE, Becker JB. The rotational behavior model: Asymmetry in the effects of unilateral 6-OHDA lesions of the substantia nigra in rats. Brain Res 1983; 264: 127-131
56. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press: Sydney, Australia; Orlando, FL, USA, 1986.